{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T17:31:43Z","timestamp":1777397503889,"version":"3.51.4"},"reference-count":44,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T00:00:00Z","timestamp":1752710400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Alzheimer\u2019s Disease"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Antipsychotic medications are frequently prescribed in people with dementia (PwD), despite concern regarding risk-benefit balance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To describe the evolution of antipsychotic prescribing for PwD in Spain, with special interest in the effect of administration regulatory warnings (2004 and 2008).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Longitudinal retrospective study using the national Spanish Database for Pharmacoepidemiological Research in Primary Care (BIFAP). We included patients with incident dementia during the study period (January 1, 2002 to December 31, 2018) and excluded those with major psychiatric conditions, mental retardation, or previous use of antipsychotics. Paper-based and electronic prescriptions of antipsychotics were collected. Annual prevalence of prescribing was obtained for single medications and antipsychotic group. All calculations were conducted for the total sample and stratified by sex. The results were compared with those of other countries.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Antipsychotic prescribing doubled during the study period, raising from 12.6% (2002) to 23.8% (2018). A mild decrease of prescribing was observed from 2004 to 2007, followed by steady increase from 2007 on. This increase was due to atypical antipsychotic use, specifically quetiapine, which grew from 0.2% (2002) to 16.4% (2018) and was more frequently utilized in men. Spain prevalence of antipsychotics doubled the UK's.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Better designed warnings appear as a key means to rationalize use of antipsychotics in Spain and other countries, ideally as part of national dementia strategies. Dearly needed non-pharmacological approaches for comprehensive treatment of neuropsychiatric symptoms could be generalized as a first step through nursing home and day care networks. Quetiapine requires the agencies\u2019 urgent attention.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/13872877251359682","type":"journal-article","created":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T06:04:24Z","timestamp":1752818664000},"page":"104-111","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Trends of antipsychotic prescribing for people with dementia in Spain"],"prefix":"10.1177","volume":"107","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7098-8494","authenticated-orcid":false,"given":"Antonio","family":"S\u00e1nchez-Soblechero","sequence":"first","affiliation":[{"name":"Neurology Department, University Hospital Gregorio Mara\u00f1\u00f3n, Madrid, Spain"},{"name":"Memory Disorders Clinic - HM Hospitals, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel","family":"Gil","sequence":"additional","affiliation":[{"name":"Spanish Agency of Medicines and Medical Devices, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Manuel","family":"Rojo","sequence":"additional","affiliation":[{"name":"Superior Council of Scientific Research, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruben","family":"Mu\u00f1iz","sequence":"additional","affiliation":[{"name":"Maria Wolff Foundation, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00aa Canto de","family":"Hoyos-Alonso","sequence":"additional","affiliation":[{"name":"Pedro La\u00edn Entralgo Health Care Center, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7320-128X","authenticated-orcid":false,"given":"Javier","family":"Olazar\u00e1n","sequence":"additional","affiliation":[{"name":"Neurology Department, University Hospital Gregorio Mara\u00f1\u00f3n, Madrid, Spain"},{"name":"Memory Disorders Clinic - HM Hospitals, Madrid, Spain"},{"name":"Maria Wolff Foundation, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2025,7,17]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2015.09.069"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1097\/00019442-200301000-00011"},{"key":"e_1_3_4_4_2","unstructured":"Benerjee S. The use of antipsychotic medication for people with dementia: Time for action https:\/\/psychrights.org\/research\/digest\/nlps\/banerjeereportongeriatricneurolepticuse.pdf2 (2009)."},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2014-006135"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.JGP.0000200589.01396.6d"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-146-11-200706050-00006"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.061250"},{"key":"e_1_3_4_9_2","unstructured":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios. Nota informativa sobre olanzapina y risperidona https:\/\/www.aemps.gob.es\/informa\/notasInformativas\/medicamentosUsoHumano\/seguridad\/2004\/NI_2004-03_olanzapina-risperidona.htm (2004)."},{"key":"e_1_3_4_10_2","unstructured":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios. Nota informativa sobre risperidona https:\/\/www.aemps.gob.es\/informa\/notasInformativas\/medicamentosUsoHumano\/seguridad\/2004\/NI_2004-04_risperidona.htm (2004)."},{"key":"e_1_3_4_11_2","unstructured":"Comunicaci\u00f3n Sobre Riesgos De Medicamentos Para Profesionales Sanitarios Nota Informativa Antipsic\u00f3ticos Cl\u00e1sicos Y Aumento De Mortalidad En Pacientes Ancianos Con Demencia https:\/\/www.aemps.gob.es\/informa\/notasInformativas\/medicamentosUsoHumano\/seguridad\/2008\/docs\/NI_2008-19_antipsicoticos.pdf (2008)."},{"key":"e_1_3_4_12_2","unstructured":"Agencia Espa\u00f1ola del Medicamento y Productos Sanitarios. BIFAP: Base de datos para la Investigaci\u00f3n Farmacoepidemiol\u00f3gica en Atenci\u00f3n Primaria http:\/\/bifap.aemps.es\/ (2023)."},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/pds.5006"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.288.12.1475"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-022-02075-8"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jamda.2014.02.003"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-2667(17)30031-2"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-150481"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2013.09.003"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-016-0366-z"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0000000000000181"},{"key":"e_1_3_4_22_2","unstructured":"Living Well With Dementia: A national dementia strategy https:\/\/www.gov.uk\/government\/publications\/living-well-with-dementia-a-national-dementia-strategy (2009)."},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1001\/archgenpsychiatry.2010.200"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2011.08.004"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.071540"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0b013e3283334f08"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0068976"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjment-2024-301019"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1177\/2040622316658463"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.0828"},{"key":"e_1_3_4_31_2","article-title":"Antipsychotics for agitation and psychosis in people with Alzheimer\u2019s disease and vascular dementia","volume":"12","author":"M\u00fchlbauer V","year":"2021","unstructured":"M\u00fchlbauer V, M\u00f6hler R, Dichter MN, et al. Antipsychotics for agitation and psychosis in people with Alzheimer\u2019s disease and vascular dementia. Cochrane Database Syst Rev 2021; 12: CD013304.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.4140\/TCP.n.2010.676"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15388"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1111\/jcpt.12357"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1159\/000510866"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1002\/pds.3527"},{"key":"e_1_3_4_37_2","article-title":"Prescribing of psychotropic medications to the elderly population of a Canadian province: a retrospective study using administrative databases","volume":"17","author":"Alessi-Severini S","year":"2013","unstructured":"Alessi-Severini S, Dahl M, Schultz J, et al. Prescribing of psychotropic medications to the elderly population of a Canadian province: a retrospective study using administrative databases. PeerJ 2013; 17: e168.","journal-title":"PeerJ"},{"key":"e_1_3_4_38_2","first-page":"488","article-title":"Antidepressant and antipsychotic prescribing in primary care for people with dementia","volume":"64","author":"Drummond N","year":"2018","unstructured":"Drummond N, McCleary L, Freiheit E, et al. Antidepressant and antipsychotic prescribing in primary care for people with dementia. Can Fam Phisician 2018; 64: 488\u2013497.","journal-title":"Can Fam Phisician"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-017-0256-8"},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.medcli.2009.07.046"},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.bp.111.107631"},{"key":"e_1_3_4_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2023.105285"},{"key":"e_1_3_4_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0197-4580(01)00231-7"},{"key":"e_1_3_4_44_2","article-title":"Withdrawal versus continuation of long-term antipsychotic drug use for behavioural and psychological symptoms in older people with dementia","volume":"1","author":"Leeuwen EV","year":"2018","unstructured":"Leeuwen EV, Petrovic M, van Driel ML, et al. Withdrawal versus continuation of long-term antipsychotic drug use for behavioural and psychological symptoms in older people with dementia. Cochrane Database Syst Rev 2018; 1: CD007726.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_4_45_2","doi-asserted-by":"publisher","DOI":"10.3233\/ADR-210015"}],"container-title":["Journal of Alzheimer\u2019s Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/13872877251359682","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/13872877251359682","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/13872877251359682","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T10:11:10Z","timestamp":1777371070000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/13872877251359682"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,17]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["10.1177\/13872877251359682"],"URL":"https:\/\/doi.org\/10.1177\/13872877251359682","relation":{},"ISSN":["1387-2877","1875-8908"],"issn-type":[{"value":"1387-2877","type":"print"},{"value":"1875-8908","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,17]]}}}